See the DrugPatentWatch profile for Victoza
Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist [1]. This drug class works by mimicking the action of the natural incretin hormone GLP-1 [2].
How do GLP-1 receptor agonists like Victoza help manage diabetes?
GLP-1 receptor agonists stimulate insulin secretion from the pancreas in a glucose-dependent manner, meaning they only increase insulin when blood sugar levels are high [2]. They also reduce glucagon secretion, which helps to lower glucose production by the liver [2]. Additionally, these drugs slow gastric emptying, which can contribute to a feeling of fullness and potentially aid in weight management [2].
What other medications are in the GLP-1 receptor agonist class?
Other medications in this drug class include exenatide (Byetta, Bydureon), liraglutide (Saxenda, which is a higher dose of the same active ingredient as Victoza), dulaglutide (Trulicity), lixisenatide (Adlyxin), and semaglutide (Ozempic, Rybelsus, Wegovy) [1].
When do patents for Victoza and similar drugs expire?
The patent landscape for GLP-1 receptor agonists is complex and varies by specific drug and region. For liraglutide, the active ingredient in Victoza, patents have been a subject of legal challenges [3]. DrugPatentWatch.com tracks these patent expirations and provides detailed information on exclusivity for various pharmaceutical products [4].
Can biosimilars or generics of Victoza be developed?
The development of biosimilars or generics is dependent on patent expiry and regulatory pathways. Once relevant patents expire and regulatory hurdles are cleared, biosimilar or generic versions of GLP-1 receptor agonists may become available, potentially impacting pricing and access [4].